IRulya Therapeutics Quarterly Income Statement
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.88-0.06 (-0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics revenue and earnings
IRulya Therapeutics reported a net loss of $27.7 million, compared with a loss of $13.4 million a year earlier. Diluted earnings per share came in at -$2.31.
Summary generated from market data by MetaCap's automated system. Methodology
IRulya Therapeutics income statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 13.14M | 79.78M | 14.59M | 19.35M | 13.43M | 10.43M | 14.86M | 12.01M | 5.86M | 28.19M | 11.22M | 9.92M |
| Research & Development | 5.85M | 5.46M | 6.84M | 12.60M | 8.08M | 6.55M | 8.14M | 5.83M | 4.92M | 4.15M | 3.70M | 3.43M |
| Operating Income | -13.14M | -79.78M | -14.59M | -19.35M | -13.43M | -10.43M | -14.86M | -12.01M | -5.86M | -28.19M | -11.22M | -9.92M |
| Other Income (Expense) | -1.62M | 152.00K | 1.72M | 660.00K | -58.00K | -29.00K | -87.00K | -518.00K | 150.00K | 91.00K | -399.00K | 402.00K |
| Pretax Income | — | — | — | — | — | — | -14.98M | — | — | — | -11.12M | — |
| Income Tax | -302.00K | 75.00K | -5.34M | 3.15M | -46.00K | 67.00K | 47.00K | 7.00K | 13.00K | 36.00K | 31.00K | 51.00K |
| Net Income | -27.74M | -75.49M | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M | -27.73M | -11.15M | -8.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.31 | -12.31 | 3.60 | 120.32 | -49.83 | -68.75 | -3.42 | -0.28 | -0.13 | -0.64 | -0.26 | -0.21 |
| EPS (Diluted) | -2.31 | -12.31 | 2.88 | 120.32 | -49.83 | -68.75 | -3.42 | -0.28 | -0.13 | -0.64 | -0.26 | -0.21 |
| Shares Outstanding (Basic) | 12.00M | 6.13M | 9.12M | — | 269.76K | 233.43K | 4.39M | — | 43.16M | 43.10M | 43.01M | — |
| Shares Outstanding (Diluted) | 12.00M | 6.13M | 9.19M | — | 269.76K | 233.43K | 4.39M | — | 43.16M | 43.10M | 43.01M | — |
| EBITDA | -13.13M | -79.74M | -14.55M | -19.31M | -13.39M | -10.39M | -14.83M | -12.00M | -5.78M | -28.15M | -11.18M | -9.62M |
This table shows 12 quarterly periods of IRulya Therapeutics's income statement, from Q3 2026 back to Q4 2023, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a income statement?